Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 21, 2013; 19(39): 6630-6636
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6630
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6630
Table 1 Characteristics of patients according to increased expression times of ABCG2 mRNA by terciles n (%)
| Clinical pathological parameters | Total cohort | ABCG2 mRNA expression times | P value | ||
| ≤0.71 (n = 40) | 0.71-1.8 (n = 23) | ≥1.8 (n =1 5) | |||
| Age (yr) | 0.123 | ||||
| Median | 59 | 58 | 61 | 59 | |
| Range | 27-81 | 27-79 | 28-81 | 30-80 | |
| Gender | 0.269 | ||||
| Female | 19 (24.4) | 10 (24.8) | 6 (28.0) | 3 (19.0) | |
| Male | 59 (75.6) | 30 (75.2) | 17 (72.0) | 12 (81.0) | |
| Performance status | 0.556 | ||||
| 0-1 | 70 (89.7) | 36 (88.8) | 20 (85.0) | 14 (91.0) | |
| 2 | 8 (10.3) | 4 (11.2) | 3 (15.0) | 1 (9.0) | |
| Histological grad | 0.106 | ||||
| Differentiated | 39 (50.0) | 19 (48.0) | 12 (51.0) | 8 (52.3) | |
| Undifferentiated | 39 (50.0) | 21 (52.0) | 11 (49.0) | 7 (47.7) | |
| Stage | 0.170 | ||||
| IIIA | 24 (30.8) | 12 (29.0) | 7 (31.0) | 5 (33.0) | |
| IIIB | 24 (30.8) | 13 (32.1) | 7 (30.0) | 4 (28.0) | |
| IV | 30 (38.5) | 15 (38.9) | 9 (39.0) | 6 (39.0) | |
| Chemotherapeutic regimen | 0.322 | ||||
| Cisplatin + fluoropyrimidine | 18 (23.1) | 9 (23.1) | 6 (26.9) | 3 (21.4) | |
| Cisplatin + docetaxel | 11 (14.1) | 6 (15.4) | 3 (14.6) | 2 (13.8) | |
| Cisplatin + paclitaxel | 10 (12.8) | 5 (12.8) | 3 (15.1) | 2 (14.3) | |
| Cisplatin + capecitabine | 19 (24.4) | 7 (32.1) | 7 (30.5) | 5 (35.8) | |
| Cisplatin + S-1 | 20 (25.6) | 13 (16.7) | 4 (12.8) | 3 (14.7) | |
- Citation: Zhang Q, Li K, Xu JH, Zhao CG, Gao Q, Wu B, Liu XY. Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer. World J Gastroenterol 2013; 19(39): 6630-6636
- URL: https://www.wjgnet.com/1007-9327/full/v19/i39/6630.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i39.6630